Dataset Information

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.

ABSTRACT:

Background

The most advanced dengue vaccine candidate is a live-attenuated recombinant vaccine containing the four dengue viruses on the yellow fever vaccine backbone (CYD-TDV) developed by Sanofi Pasteur. Several analyses have been published on the safety and immunogenicity of the CYD-TDV vaccine from single trials but none modelled the heterogeneity observed in the antibody responses elicited by the vaccine.

Methods

We analyse the immunogenicity data collected in five phase-2 trials of the CYD-TDV vaccine. We provide a descriptive analysis of the aggregated datasets and fit the observed post-vaccination PRNT50 titres against the four dengue (DENV) serotypes using multivariate regression models.

Results

We find that the responses to CYD-TDV are principally predicted by the baseline immunological status against DENV, but the trial is also a significant predictor. We find that the CYD-TDV vaccine generates similar titres against all serotypes following the third dose, though DENV4 is immunodominant after the first dose.

Conclusions

This study contributes to a better understanding of the immunological responses elicited by CYD-TDV. The recent availability of phase-3 data is a unique opportunity to further investigate the immunogenicity and efficacy of the CYD-TDV vaccine, especially in subjects with different levels of pre-existing immunity against DENV. Modelling multiple immunological outcomes with a single multivariate model offers advantages over traditional approaches, capturing correlations between response variables, and the statistical method adopted in this study can be applied to a variety of infections with interacting strains.

SUBMITTER: Dorigatti I

PROVIDER: S-EPMC4504002 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.

Dorigatti Ilaria I Aguas Ricardo R Donnelly Christl A CA Guy Bruno B Coudeville Laurent L Jackson Nicholas N Saville Melanie M Ferguson Neil M NM

Vaccine 20150604 31

<h4>Background</h4>The most advanced dengue vaccine candidate is a live-attenuated recombinant vaccine containing the four dengue viruses on the yellow fever vaccine backbone (CYD-TDV) developed by Sanofi Pasteur. Several analyses have been published on the safety and immunogenicity of the CYD-TDV vaccine from single trials but none modelled the heterogeneity observed in the antibody responses elicited by the vaccine.<h4>Methods</h4>We analyse the immunogenicity data collected in five phase-2 tr ...[more]

PMID: 26051515

Similar Datasets

Project description:There is great untapped potential for farm mechanization to support rural development initiatives in low- and middle-income countries. As technology transfer of large machinery from high-income countries was ineffective during the 1980s and 90s, mechanization options were developed appropriate to resource poor farmers cultivating small and scattered plots. More recently, projects that aim to increase the adoption of farm machinery have tended to target service providers rather than individual farmers. This paper uses the Scaling Scan tool to assess three project case studies designed to scale different Mechanization Service Provider Models (MSPMs) in Mexico, Zimbabwe, and Bangladesh. It provides a useful framework to assess the gap between international lessons learned on scaling captured in forty tactical questions over ten "scaling ingredients" as perceived by stakeholders involved in the projects, as well as private sector actors and government employees. Although at first sight the case studies seem to successfully reach high numbers of end users, the assessment exposes issues around the sustainable and transformative nature of the interventions. These are highly influenced by the design of the projects and by the environment and context of the intervention areas. Across the three case studies, large-scale adoption of the models was found to be hampered by lack of finance to set up MSPMs and insufficient collaboration among the value chain actors to strengthen and foster Mechanization Service Provider (MSP) entrepreneurs. Applying a scaling perspective on each case study project exposed important lessons on minimizing project dependencies. Positive examples include integration of capacity development materials in vocational training centers in Zimbabwe, promotion of MSPMs by other donors in East Africa and levering of nearly USD six million of private sector investment in appropriate machinery in Bangladesh. On the other hand, there is still a high dependency on the projects in terms of coaching of service providers, facilitating collaboration along the value chain, and provision of leadership and advocacy to address issues at governance level. These results have important implications for similar development interventions aimed at increasing smallholder access to mechanization services at scale and is to our knowledge the first cross-continental assessment of these issues to date.

Dataset Information

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.

Background

Methods

Results

Conclusions

Publications

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure